APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast 2026-2032

20 December 2025193 pages

Choose your research edition.

Industry ResearchDiphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine include Astellas Pharma US, Emergent BioSolutions Inc, Merck Sharp & Dohme Corp, Protein Sciences Corporation, Sanofi Pasteur, Seqirus, AstraZeneca, GlaxoSmithKline and Pfizer Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales, projected growth trends, production technology, application and end-user industry.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Company

Astellas Pharma US

Emergent BioSolutions Inc

Merck Sharp & Dohme Corp

Protein Sciences Corporation

Sanofi Pasteur

Seqirus

AstraZeneca

GlaxoSmithKline

Pfizer Inc

Lanzhou Institute of Biological Products Co., Ltd

Novartis AG

Johnson & Johnson

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Type

Immune DTaP Vaccine

Therapy DTaP Vaccine

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Application

Adult

Pediatric

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Immune DTaP Vaccine Major Manufacturers Table 3. Therapy DTaP Vaccine Major Manufacturers Table 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Adult Major Manufacturers Table 6. Pediatric Major Manufacturers Table 7. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends Table 8. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Drivers Table 9. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Opportunities and Challenges Table 10. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Restraints Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2021-2026) Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2027-2032) Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021-2026) & (W Units) Table 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2027-2032) & (W Units) Table 19. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2021-2026) Table 20. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2027-2032) Table 21. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2021-2026) Table 25. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers, Product Type & Application Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2026) Table 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2027-2032) Table 37. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 38. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 39. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 40. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2026) Table 41. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2027-2032) Table 42. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2026) & (US$/Unit) Table 43. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2027-2032) & (US$/Unit) Table 44. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2026) Table 48. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2027-2032) Table 49. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 50. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 51. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 52. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2026) Table 53. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2027-2032) Table 54. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2026) & (US$/Unit) Table 55. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2027-2032) & (US$/Unit) Table 56. Astellas Pharma US Company Information Table 57. Astellas Pharma US Business Overview Table 58. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 60. Astellas Pharma US Recent Development Table 61. Emergent BioSolutions Inc Company Information Table 62. Emergent BioSolutions Inc Business Overview Table 63. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 65. Emergent BioSolutions Inc Recent Development Table 66. Merck Sharp & Dohme Corp Company Information Table 67. Merck Sharp & Dohme Corp Business Overview Table 68. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 70. Merck Sharp & Dohme Corp Recent Development Table 71. Protein Sciences Corporation Company Information Table 72. Protein Sciences Corporation Business Overview Table 73. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 75. Protein Sciences Corporation Recent Development Table 76. Sanofi Pasteur Company Information Table 77. Sanofi Pasteur Business Overview Table 78. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 80. Sanofi Pasteur Recent Development Table 81. Seqirus Company Information Table 82. Seqirus Business Overview Table 83. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 85. Seqirus Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 90. AstraZeneca Recent Development Table 91. GlaxoSmithKline Company Information Table 92. GlaxoSmithKline Business Overview Table 93. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 95. GlaxoSmithKline Recent Development Table 96. Pfizer Inc Company Information Table 97. Pfizer Inc Business Overview Table 98. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 100. Pfizer Inc Recent Development Table 101. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 102. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 103. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 105. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 106. Novartis AG Company Information Table 107. Novartis AG Business Overview Table 108. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 110. Novartis AG Recent Development Table 111. Johnson & Johnson Company Information Table 112. Johnson & Johnson Business Overview Table 113. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 115. Johnson & Johnson Recent Development Table 116. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 119. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 120. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 121. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 122. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 123. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 124. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 125. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 126. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 127. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 128. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 130. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 131. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 132. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 133. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 134. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 135. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 136. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 137. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 138. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 139. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 140. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 141. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 142. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 143. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 144. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 145. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 146. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 147. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 148. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 149. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 150. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 152. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 153. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 154. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 155. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 156. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 157. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 158. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 159. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 160. U.K. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 161. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 162. Netherlands Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 163. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 164. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 165. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 166. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 167. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 168. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 169. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 170. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 171. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 172. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 173. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 174. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 175. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 176. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 177. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 178. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 179. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 180. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 181. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 182. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 183. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 184. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 185. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 186. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 187. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 188. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 189. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 190. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 191. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 192. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 193. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 194. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 195. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 196. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 197. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 198. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 199. China Taiwan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 200. Southeast Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 201. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 202. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 203. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 204. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 205. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 206. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 207. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 208. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 209. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 210. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 211. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 212. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 213. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 214. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 215. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 216. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 217. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 218. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2027-2032) & (W Units) Table 219. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 220. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 221. Brazil Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 222. Argentina Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 223. Chile Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 224. Colombia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 225. Peru Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 226. Saudi Arabia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 227. Israel Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 228. UAE Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 229. Turkey Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 230. Iran Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 231. Egypt Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Table 232. Key Raw Materials Table 233. Raw Materials Key Suppliers Table 234. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List Table 235. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List Table 236. Research Programs/Design for This Report Table 237. Authors List of This Report Table 238. Secondary Sources Table 239. Primary Sources List of Figures Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Image Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Immune DTaP Vaccine Image Figure 5. Therapy DTaP Vaccine Image Figure 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Adult Image Figure 9. Pediatric Image Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2032) & (US$ Million) Figure 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2021-2032) Figure 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2021-2032) & (W Units) Figure 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2021-2032) & (W Units) Figure 19. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2021-2032) & (W Units) Figure 20. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2021-2032) & (W Units) Figure 21. Asia (Excluding China) Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2021-2032) & (W Units) Figure 22. South America, Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales YoY (2021-2032) & (W Units) Figure 23. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2032) Figure 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2032) Figure 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2032) Figure 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2032) Figure 38. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2021-2032) Figure 39. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2021-2032) Figure 40. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2021-2032) Figure 41. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2021-2032) Figure 42. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2021-2032) Figure 43. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2021-2032) Figure 44. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2021-2032) Figure 45. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2021-2032) Figure 46. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2021-2032) Figure 47. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2021-2032) Figure 48. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2021-2032) Figure 49. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2021-2032) Figure 50. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2021-2032) Figure 51. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2021-2032) Figure 52. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2021-2032) Figure 53. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2021-2032) Figure 54. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2021-2032) Figure 55. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2021-2032) Figure 56. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2021-2032) Figure 57. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2021-2032) Figure 58. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2021-2032) Figure 59. Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country (2021-2032) Figure 60. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Type (2021-2032) Figure 61. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Type (2021-2032) Figure 62. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Application (2021-2032) Figure 63. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Application (2021-2032) Figure 64. SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Country (2021-2032) Figure 65. SAMEA Diphtheria, Tetanus, and Pertussis (D

Scope & coverage.

Types
  • Immune DTaP Vaccine
  • Therapy DTaP Vaccine
Applications
  • Adult
  • Pediatric
Companies covered
  • Astellas Pharma US
  • Emergent BioSolutions Inc
  • Merck Sharp & Dohme Corp
  • Protein Sciences Corporation
  • Sanofi Pasteur
  • Seqirus
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer Inc
  • Lanzhou Institute of Biological Products Co., Ltd
  • Novartis AG
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Type
  3. 1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Immune DTaP Vaccine
  5. 1.2.3 Therapy DTaP Vaccine
  6. 1.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Application
  7. 1.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Adult
  9. 1.3.3 Pediatric
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Dynamics
  1. 2.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
  2. 2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Drivers
  3. 2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Opportunities and Challenges
  4. 2.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region
  3. 3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region
  9. 3.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers
  6. 4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Tier 1, Tier 2, and Tier 3
5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Type
  1. 5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type
  2. 5.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type
  6. 5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type
6 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Application
  1. 6.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application
  2. 6.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application
  6. 6.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application
7 Company Profiles
  1. 7.1 Astellas Pharma US
  2. 7.1.1 Astellas Pharma US Company Information
  3. 7.1.2 Astellas Pharma US Business Overview
  4. 7.1.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  6. 7.1.5 Astellas Pharma US Recent Developments
  7. 7.2 Emergent BioSolutions Inc
  8. 7.2.1 Emergent BioSolutions Inc Company Information
  9. 7.2.2 Emergent BioSolutions Inc Business Overview
  10. 7.2.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  12. 7.2.5 Emergent BioSolutions Inc Recent Developments
  13. 7.3 Merck Sharp & Dohme Corp
  14. 7.3.1 Merck Sharp & Dohme Corp Company Information
  15. 7.3.2 Merck Sharp & Dohme Corp Business Overview
  16. 7.3.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  18. 7.3.5 Merck Sharp & Dohme Corp Recent Developments
  19. 7.4 Protein Sciences Corporation
  20. 7.4.1 Protein Sciences Corporation Company Information
  21. 7.4.2 Protein Sciences Corporation Business Overview
  22. 7.4.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  24. 7.4.5 Protein Sciences Corporation Recent Developments
  25. 7.5 Sanofi Pasteur
  26. 7.5.1 Sanofi Pasteur Company Information
  27. 7.5.2 Sanofi Pasteur Business Overview
  28. 7.5.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  30. 7.5.5 Sanofi Pasteur Recent Developments
  31. 7.6 Seqirus
  32. 7.6.1 Seqirus Company Information
  33. 7.6.2 Seqirus Business Overview
  34. 7.6.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  36. 7.6.5 Seqirus Recent Developments
  37. 7.7 AstraZeneca
  38. 7.7.1 AstraZeneca Company Information
  39. 7.7.2 AstraZeneca Business Overview
  40. 7.7.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  42. 7.7.5 AstraZeneca Recent Developments
  43. 7.8 GlaxoSmithKline
  44. 7.8.1 GlaxoSmithKline Company Information
  45. 7.8.2 GlaxoSmithKline Business Overview
  46. 7.8.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  48. 7.8.5 GlaxoSmithKline Recent Developments
  49. 7.9 Pfizer Inc
  50. 7.9.1 Pfizer Inc Company Information
  51. 7.9.2 Pfizer Inc Business Overview
  52. 7.9.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  54. 7.9.5 Pfizer Inc Recent Developments
  55. 7.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 7.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 7.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 7.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  60. 7.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 7.11 Novartis AG
  62. 7.11.1 Novartis AG Company Information
  63. 7.11.2 Novartis AG Business Overview
  64. 7.11.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  66. 7.11.5 Novartis AG Recent Developments
  67. 7.12 Johnson & Johnson
  68. 7.12.1 Johnson & Johnson Company Information
  69. 7.12.2 Johnson & Johnson Business Overview
  70. 7.12.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  72. 7.12.5 Johnson & Johnson Recent Developments
8 North America
  1. 8.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
  2. 8.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2032)
  5. 8.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
  6. 8.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2032)
  9. 8.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  10. 8.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
  2. 9.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
  6. 9.2.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  10. 9.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
  2. 10.1.1 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2032)
  5. 10.2 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
  6. 10.2.1 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
  2. 11.1.1 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
  6. 11.2.1 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  10. 11.3.1 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
  2. 12.1.1 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
  6. 12.2.1 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  10. 12.3.1 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain Analysis
  2. 13.1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
  6. 13.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
  9. 13.2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst